SangStat Announces Record Fourth-Quarter and 2000 Revenues; Expects to Build on Success in 2001.

Health Editors/Medical Writers

FREMONT, Calif.--(BW HealthWire)--Jan. 22, 2001

SangStat (Nasdaq:SANG) announced today record fourth quarter and full-year 2000 unaudited revenues. Audited financial results will be released on February 13, 2001.

SangStat's revenues of $23M for the fourth quarter represents a 7% sequential increase compared to revenues of $21.5M for the third quarter and a 25% increase compared to revenues of $18.4M for the fourth quarter of 1999. Full year revenues for 2000 were $80.8M, up 39% from revenues of $58.2M for the previous year. SangStat expects to report a loss per share between $0.30 and $0.32 for the fourth quarter, a significant improvement over the consensus of a loss of $0.35 per share.

"We are very excited about the company's potential in the future," said Jean-Jacques Bienaime, SangStat's Chairman, President and CEO. "This past year was a time of transition for SangStat. As we begin this new year, we are pleased to be able to demonstrate that we are on track for achieving our objectives and hitting our milestones. We anticipate continued improvement in EPS for the coming quarters as a result of continued success with sales of therapeutic products and ongoing expense reduction."

SangStat recently reported on progress and successes in its clinical development programs. Highlights included the potential therapeutic market expansion of Thymoglobulin (Anti-thymocyte Globulin, (Rabbit)), subject to FDA approval, through SangStat's clinical development program which now has over 200 patients enrolled in a variety of trials. In addition, the ABX-CBL patient trial for the treatment of acute graft versus host disease now has over one third of patients (35) already enrolled.

SangStat's full financial results for the fourth quarter and guidance going forward will be released on February 13, 2001, after the close of the market. Following the release SangStat will host an investor conference call. The call will be held at 4:30pm EST on Tuesday, February 13th and can be accessed by dialing 1-888-552-9483; the passcode is 2003936.

SangStat

SangStat is a global biotechnology company building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. Since 1988, SangStat has been dedicated to improving the outcome of organ and bone marrow transplantation through the development and marketing of products to address all phases of transplantation in the worldwide market. SangStat's US headquarters are in Fremont, California. SangStat also maintains a strong European presence, including direct sales and marketing forces in France, Germany, Italy, Spain, and the U.K., and distributors throughout the rest of the world. SangStat's stock is traded on the Nasdaq under the symbol "SANG". The company's web site is located at www.sangstat.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the company's (1) outcome of its audit of fiscal year 2000 financial statements, (2) the timing of achievement of previously announced objectives and milestones, (3) product development and potential future sales, (4) opportunities for future growth and development of new markets; (5) potential reductions in expenses; and (6) expected financial results including future revenues, expenses, charges, and earnings/losses per share. Forward-looking statements reflect SangStat's current views with respect to future events. Actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated. There can be no assurance that upon audit these estimates will not be revised, that any product candidate under development will be safe, effective, receive regulatory approval, or if approved, will be capable of being manufactured in commercial quantities at an economical cost, will not infringe the proprietary rights of others or will achieve market acceptance. There can be no assurance that the company will be able to fulfill its commitments or meet its goals, effectively utilize its resources, take advantage of opportunities for growth in new or existing markets, reduce expenses, or meet its financial goals, including revenues, expenses, and earnings/losses per share. Other factors that could cause actual results to differ materially include, without limitation, unforeseen market developments such as new competitors or increased sales by current competitors, reduction of margins on key products, reduction in demand or failure of demand to reach anticipated levels, the inability to reduce expenses due to fixed costs, delays in clinical trial enrollment which could delay regulatory filings and approvals, and changes in reimbursement for products. For a discussion of these and other factors that might result in different outcomes, see "Risk Factors" in SangStat's 1999 Annual Report on Form 10-K, its 2000 quarterly reports on Form 10-Q and other documents (including registration statements on Form S-3) filed with the Securities and Exchange Commission.